Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07036029 · ClinicalTrials.gov registry record · Phase 1
NAL ER IPF Respiratory Function and Safety Study
A Phase 1 study of Idiopathic Pulmonary Fibrosis, sponsored by Trevi Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 2
- Study locations
NCT07036029 is a Phase 1 study of Idiopathic Pulmonary Fibrosis that is actively recruiting participants, run by Trevi Therapeutics. The registered enrollment target is 10 participants, below the 751-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT07036029, a Phase 1 study of Idiopathic Pulmonary Fibrosis, is actively recruiting participants, sponsored by Trevi Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 2
- Study locations
Study Summary
The primary purpose of this study is to assess the safety and tolerability of escalating doses of NAL ER and to evaluate its effect on respiratory function in participants with IPF.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG NAL ER
Study Locations (2)
Minnesota
- Mayo Clinic - Rochester
Other
- Medicines Evaluation Unit Ltd. - Manchester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-08-21 |
| Est. Completion | 2026-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07036029
The ClinicalTrials.gov registry entry for NCT07036029 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 751-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (99% lower). The listed sponsor is Trevi Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Idiopathic Pulmonary Fibrosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07036029 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Minnesota, Other.
Frequently Asked Questions
What is clinical trial NCT07036029 about?
NCT07036029 is a clinical study titled "NAL ER IPF Respiratory Function and Safety Study". The primary purpose of this study is to assess the safety and tolerability of escalating doses of NAL ER and to evaluate its effect on respiratory function in participants with IPF.
What is the current status of trial NCT07036029?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2025-08-21. Estimated completion is 2026-04.
What conditions does trial NCT07036029 study?
This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis.
What interventions are being tested in trial NCT07036029?
The interventions under investigation include: Placebo (DRUG), NAL ER (DRUG).
Who is sponsoring clinical trial NCT07036029?
This trial is sponsored by Trevi Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07036029 being conducted?
This trial has 2 study locations across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Pulmonary Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dose-Escalation Study of Artesunate Patients With IPF
RECRUITING · Phase 1
-
Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure
RECRUITING · Phase 1
-
A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GNS-3545 in Healthy Participants
RECRUITING · Phase 1
-
Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 1
-
Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients
ACTIVE NOT RECRUITING · Phase 1
-
Atezolizumab for Idiopathic Pulmonary Fibrosis
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.